![AstraZeneca PLC Website](https://cdn.finchat.io/336774.png)
AstraZeneca PLC
LSE-AZN
Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Name
AstraZeneca PLC
CEO
Mr. Pascal Soriot D.V.M., M.B.A.
Website
www.astrazeneca.com
Sector
Pharmaceuticals
Year Founded
1992
Profile
Market Cap
£196.11B
EV
£217.2B
Shares Out
1,550.29M
Revenue
$49.13B
Employees
89,900
Margins
Gross
82.62%
EBITDA
34.55%
Operating
25.13%
Pre-Tax
15.77%
Net
13.11%
FCF
19.18%
Returns (5Yr Avg)
ROA
3.67%
ROTA
-204.57%
ROE
12.68%
ROCE
10.32%
ROIC
8.24%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
£139.56
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$7,076M
Net Debt
$26.57B
Debt/Equity
0.85
EBIT/Interest
9.65
Growth (CAGR)
Rev 3Yr
18.5%
Rev 5Yr
16.32%
Rev 10Yr
6.44%
Dil EPS 3Yr
12.79%
Dil EPS 5Yr
19.2%
Dil EPS 10Yr
9.9%
Rev Fwd 2Yr
10.73%
EBITDA Fwd 2Yr
22.18%
EPS Fwd 2Yr
13.71%
EPS LT Growth Est
13.45%
Dividends
Yield
—
Payout
71.44%
DPS
$2.97
DPS Growth 3Yr
1.98%
DPS Growth 5Yr
1.19%
DPS Growth 10Yr
0.59%
DPS Growth Fwd 2Yr
5.9%